Some years ago, a mutated IL-2 (termed no-alpha mutein) was developed which has a disrupted affinity for the high affinity IL-2R, expands preferentially CD8+ T lymphocytes and NK cells over Tregs (25, 26) and exerts a higher anti-metastatic effect than IL-2 in 3LL-D122 and B16 tumor models (25). Here, CD8A is linked to neoplasm.